gdc
PSSGuide_2021
Colorectal Cancer

Drugs for Colorectal Cancer

Here are the drugs and financial support services available to patients receiving treatment for Colorectal Cancer.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used as a first-line or second-line treatment for patients with metastatic colorectal cancer, together with IV chemotherapy. Avastin is also used as a second-line treatment, in combination with other types of chemotherapy, in patients with metastatic colorectal cancer whose disease progressed with a first-line Avastin-containing regimen.

Genentech Oncology provides 2 financial assistance programs for patients who are using Avastin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Braftovi (encorafenib)

Drug company: Pfizer
877-744-5675

Braftovi is an oral kinase inhibitor used, in combination with cetuximab, for the treatment of adults with previously treated metastatic colorectal cancer that is associated with a BRAF V600E mutation, as detected by an FDA-approved test.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Braftovi:

Co-Pay Assistance Program

Eligible, commercially insured patients may pay as little as $0 per month for Braftovi. This program has no income requirements, forms, or faxing to enroll.

Pfizer Patient Assistance Program

Patients with Medicare Part D, Medicaid, or any other government insurance plan may be able to receive Braftovi for free through Pfizer Oncology Together and Pfizer Patient Assistance. Uninsured patients may be able to receive Braftovi for free through the Pfizer Patient Assistance Program, or at a savings through the Pfizer Savings Program.

Camptosar (irinotecan hydrochloride) injection

Drug company: Pfizer
877-744-5675

Camptosar is a topoisomerase inhibitor used as a first-line therapy, in combination with a chemotherapy regimen, for patients with metastatic carcinoma of the colon or the rectum (colorectal cancer). Camptosar is also used for patients with metastatic carcinoma of the colon or rectum whose disease has returned or progressed after chemotherapy.

Pfizer Oncology Together provides 1 financial assistance program for patients using Camptosar:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Camptosar, and meet certain income limits but have no drug perscription coverage or insufficient coverage to pay for Camptosar, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used in combination with chemotherapy for patients with metastatic colorectal cancer that progressed during or after therapy with Avastin, Eloxatin, and a fluoropyrimidine

Lilly Oncology provides 2 financial assistance programs for patients using Cyramza:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $63,800 for 1 person; $86,200 for 2 people; $108,600 for 3 people; $131,000 for 4 people; $153,400 for 5 people; $175,800 for 6 people, this program provides Cyramza at no cost.

Erbitux (cetuximab)

Drug company: Eli Lilly
866-472-8663

Erbitux is an EGFR antagonist used for the treatment of patients with KRAS wild-type, EGFR-expressing, metastatic colorectal cancer in combination with a chemotherapy regimen for first-line treatment, in combination with Camptosar for patients who cannot use Camptosar-based chemotherapy, or as a single drug for patients who have not benefited from Eloxatin- and Camptosar-based chemotherapy, or who cannot use Camptosar.

Lilly Oncology provides 2 financial assistance programs for patients using Erbitux:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Erbitux.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $63,800 for 1 person; $86,200 for 2 people; $108,600 for 3 people; $131,000 for 4 people; $153,400 for 5 people; $175,800 for 6 people, this program provides Erbitux at no cost.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (dMMR) colorectal cancer.

Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $60,700 or less for individuals, $82,300 or less for a couple, or $125,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lonsurf (trifluridine + tipiracil) Tablets

Drug company: Taiho Oncology
844-824-4648

Lonsurf is a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor used for patients with metastatic colorectal cancer who have previously received chemotherapy, an anti-VEGF biological therapy, and if their cancer is KRAS wild-type, an anti-EGFR therapy.

Taiho Oncology Patient Support provides 2 financial assistance programs for patients using Lonsurf:

Taiho Oncology Patient Support Co-pay Card

Patients with private insurance may be eligible to receive a copay card to help them to pay $30 out-of-pocket expenses for a treatment cycle of Lonsurf.

Taiho Oncology Patient Support Program

This program may provide Lonsurf free of charge for patients who have no insurance or insufficient prescription coverage and insufficient financial resources.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with chemotherapy, for first- or second-line treatment of patients with metastatic colorectal cancer, or used for second-line treatment after disease progression with a first-line bevacizumab-containing regimen.

Amgen offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D insurance, who satisfy the income eligibility requirements may receive Mvasi for free.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used alone, or in combination with Yervoy, for the treatment of patients age 12 years or older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS medications used in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for patients with metastatic colorectal cancer who have previously received chemotherapy, an anti-VEGF therapy, or if their cancer is RAS wildtype (no RAS mutation), an anti-EGFR therapy.

Bayer provides 2 financial assistance programs for patients using Stivarga:

STIVARGA $0 Co-pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Vectibix (panitumumab)

Drug company: Amgen
888-427-7478

Vectibix is an EGFR antagonist used for patients with KRAS wild-type metastatic colorectal cancer as first-line treatment in combination with a chemotherapy regimen, or alone when their disease progresses after treatment with a chemotherapy regimen.

Amgen provides 2 financial assistance programs for patients using Vectibix:

Vectibix FIRST STEP Program

For patients with private insurance whose insurance covers Vectibix, this program ensures a copay of $0 for the first dose and $5 for each dose thereafter, with a maximum benefit of $10,000 per patient, annually.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements can receive Vectibix for free through this nonprofit program from Amgen.

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Xeloda is a nucleoside metabolic inhibitor with antineoplastic activity used as adjuvant treatment for patients with Dukes’ C colon cancer, and as a first-line therapy alone for patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred.

Genentech Oncology provides 1 financial support program for patients who are prescribed Xeloda:

Genentech Patient Foundation

This foundation provides Xeloda free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Yervoy (ipilimumab)

Drug company: Bristol Myers Squibb
800-861-0048

Yervoy is a human cytotoxic T-lymphocyte antigen 4–blocking antibody used, in combination with Opdivo, for the treatment of patients age 12 years or older with microsatellite instability- high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication (or $50,000 annually for 2 BMS medications used in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Zaltrap (ziv-aflibercept)

Drug company: Sanofi Genzyme
833-930-2273

Zaltrap, in combination with a chemotherapy regimen, is used for patients with metastatic colorectal cancer that is resistant to or has progressed after an Eloxatin-containing regimen.

Sanofi Genzyme provide 2 financial assistance programs for patients who are prescribed Zaltrap:

CareASSIST Copay Program

Eligible patients with commercial insurance may pay as little as $0 for Zaltrap. The Copay Program covers the drug cost up to a $25,000 benefit annually. Patients are responsible for any out-of-pocket costs for Zaltrap over the benefit limit. Patients must have commercial or private insurance, including state or federal employee plans and health insurance exchanges. This program has no income requirements to qualify.

CareASSIST Patient Support Program

Patients with no insurance coverage or no access to Zaltrap may be eligible for assistance through the Sanofi Genzyme CareASSIST Patient Support Program, including access to medication at no cost. Patients must not be eligible for government- based insurance, and their annual household income must not be more than $100,000, or 500% of the federal poverty level. Patients enrolled in Medicare Part B who have no supplemental insurance may be eligible to receive Zaltrap through this program. If you do not meet Zaltrap requirements, contact a CareASSIST Patient Access Specialist at www.sanoficareassist.com.

Zirabev (bevacizumab-bvzr)

Drug company: Pfizer
877-744-5675

Zirabev, a biosimilar to Avastin, is a VEGF inhibitor used for the first- or second-line treatment, in combination with fluorouracil- based chemotherapy, of patients with metastatic colorectal cancer, and in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, for the second-line treatment of patients with metastatic colorectal cancer whose disease progressed during a first-line regimen containing a bevacizumab drug.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Zirabev is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Zirabev for free or at a savings. Eligible patients with government insurance may also receive Zirabev for free if they cannot find independent charitable foundation support.

Table. Drugs Prescribed for Colorectal Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab) Injection
  • Drug company
  • Genentech
  • Indication
  • First-line or second-line therapy for metastatic colorectal cancer, in combination with IV-based chemotherapy

    Second-line treatment, in combination with a chemotherapy regimen, for metastatic colorectal cancer that progressed with a first-line Avastincontaining regimen
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Braftovi (encorafenib)
  • Drug company
  • Pfizer
  • Indications
  • Treatment of adults with metastatic colorectal cancer and BRAF V600E mutation, as detected by an FDA-approved test
  • Patient support services
  • Co-Pay Assistance Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Camptosar (irinotecan hydrochloride) injection
  • Drug company
  • Pfizer
  • Indications
  • First-line therapy for metastatic carcinoma of the colon or rectum, in combination with 5-fluorouracil and leucovorin

    Second-line therapy for metastatic carcinoma of the colon or rectum, after chemotherapy
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675





    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of metastatic colorectal cancer, in combination with chemotherapy, or after disease progression with bevacizumab-containing regimen
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436



    Drug name (generic name)
  • Vectibix (panitumumab)
  • Drug company
  • Amgen
  • Indication
  • First-line therapy of metastatic colorectal cancer, in combination with chemotherapy

    Metastatic colorectal cancer, after chemotherapy
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indication
  • Adjuvant therapy for colon cancer, specifically Dukes’ C colon cancer

    First-line therapy for metastatic colorectal cancer
  • Patient support services
  • Genentech Patient Foundation
    888-941-3331



    Drug name (generic name)
  • Zirabev (bevacizumabbvzr)
  • Drug company
  • Pfizer
  • Indication
  • First- or second-line treatment, in combination with fluorouracil-based chemotherapy, of metastatic colorectal cancer

    Second-line treatment, in combination with fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin- based chemotherapy, of metastatic colorectal cancer in patients whose disease progressed during a firstline regimen containing a bevacizumab drug
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675
dMMR indicates mismatch repair-deficient; MSI-H, microsatellite instability-high.

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country